

# Maria Rosaria Valerio

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8899310/publications.pdf>

Version: 2024-02-01

38  
papers

1,279  
citations

759055

12  
h-index

360920

35  
g-index

39  
all docs

39  
docs citations

39  
times ranked

1777  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell'€™Italia Meridionale. <i>Journal of Clinical Oncology</i> , 2005, 23, 4866-4875.	0.8	693
2	Topotecan Compared With No Therapy After Response to Surgery and Carboplatin/Paclitaxel in Patients With Ovarian Cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) Randomized Study. <i>Journal of Clinical Oncology</i> , 2004, 22, 2635-2642.	0.8	149
3	Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients's™ Queries, Needs, Fears, and Actions Taken. <i>JCO Global Oncology</i> , 2020, 6, 722-729.	0.8	54
4	Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma. <i>Anticancer Research</i> , 2012, 32, 529-36.	0.5	38
5	Salvage Therapy With Oral Metronomic Cyclophosphamide and Methotrexate for Castration-refractory Metastatic Adenocarcinoma of the Prostate Resistant to Docetaxel. <i>Urology</i> , 2011, 78, 1125-1130.	0.5	33
6	First-Line Treatment With Epirubicin and Vinorelbine in Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 2689-2694.	0.8	31
7	Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer. <i>Pulmonary Therapy</i> , 2021, 7, 295-308.	1.1	25
8	TP53 in gastric cancer: Mutations in the L3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome. <i>Journal of Cellular Physiology</i> , 2004, 200, 476-485.	2.0	24
9	DNA aneuploidy and high proliferative activity but not K-ras-2 mutations as independent predictors of clinical outcome in operable gastric carcinoma. <i>Cancer</i> , 2001, 92, 294-302.	2.0	23
10	Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1€™3 node-positive rapidly proliferating breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 125, 775-784.	1.1	19
11	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	2.0	19
12	Current Role of Intraoperative Frozen Section Examination of Sentinel Lymph Node in Early Breast Cancer. <i>Anticancer Research</i> , 2020, 40, 1711-1717.	0.5	16
13	TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. <i>Journal of Cellular Physiology</i> , 2006, 206, 181-188.	2.0	13
14	Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy. <i>Case Reports in Oncological Medicine</i> , 2017, 2017, 1-4.	0.2	12
15	High-dose Radiotherapy for Oligo-progressive NSCLC Receiving EGFR Tyrosine Kinase Inhibitors: Real World Data. <i>In Vivo</i> , 2020, 34, 2009-2014.	0.6	12
16	Abemaciclib: safety and effectiveness of a unique cyclin-dependent kinase inhibitor. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 945-954.	1.0	11
17	Metastatic seeding of colon adenocarcinoma manifesting as synchronous breast and chest wall localization: Report of a case. <i>Surgery Today</i> , 2011, 41, 242-246.	0.7	9
18	Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor: Data From the Real World. <i>Anticancer Research</i> , 2020, 40, 7037-7043.	0.5	9

#	ARTICLE	IF	CITATIONS
19	Is G8 geriatric assessment tool useful in managing elderly patients with metastatic pancreatic carcinoma?. <i>Journal of Geriatric Oncology</i> , 2021, 12, 163-167.	0.5	9
20	A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 96, 97-100.	1.1	8
21	Does Smoking Cessation at Primary Diagnosis Reduce the Recurrence Risk of Nonmuscle-Invasive Bladder Cancer? Results of a Prospective Study. <i>Urologia Internationalis</i> , 2020, 104, 396-401.	0.6	8
22	Nm23-H1 expression does not predict clinical survival in colorectal cancer patients. <i>Oncology Reports</i> , 2003, 10, 1257-63.	1.2	8
23	WhatsApp Messenger use in oncology: a narrative review on pros and contras of a flexible and practical, non-specific communication tool. <i>Ecancermedalscience</i> , 2021, 15, 1334.	0.6	7
24	Escalating doses of paclitaxel and epirubicin in combination with cisplatin in advanced ovarian epithelial carcinoma: a phase II study. <i>Anti-Cancer Drugs</i> , 2003, 14, 359-364.	0.7	6
25	PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110598.	1.4	6
26	Clinical Presentation and Treatment of Gastrointestinal Stromal Tumors. <i>Tumori</i> , 2006, 92, 279-284.	0.6	5
27	Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial. <i>International Journal of Medical Sciences</i> , 2021, 18, 2245-2250.	1.1	5
28	Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis. <i>Future Science OA</i> , 2021, 7, FSO750.	0.9	5
29	Cigarette smoking habit does not reduce the benefit from first line trastuzumab-based treatment in advanced breast cancer patients. <i>Oncology Reports</i> , 2011, 25, 1545-8.	1.2	4
30	Axillary Nodal Burden in Breast Cancer Patients With Pre-operative Fine Needle Aspiration-proven Positive Lymph Nodes Compared to Those With Positive Sentinel Nodes. <i>In Vivo</i> , 2020, 34, 729-734.	0.6	4
31	Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9). <i>Breast Cancer Research and Treatment</i> , 2021, 190, 103-109.	1.1	3
32	Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 964-969.	0.8	2
33	EGFR tyrosine kinase inhibitor therapy continuation with high-dose hypofractionated radiotherapy in EGFR-mutated non-small cell lung cancer (NSCLC) patients with oligoprogressive disease.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21580-e21580.	0.8	2
34	NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 609-613.	0.5	1
35	Harmful Interference of Detoxifying Diets and Nutraceuticals with Adherence to Abemaciclib in Advanced Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Breast Cancer: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 1399-1406.	0.3	1
36	Safety of trastuzumab, alone or in combination, in elderly patients with HER2-positive breast cancer: A 5-year case series.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11056-e11056.	0.8	1

#	ARTICLE	IF	CITATIONS
37	Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VICTOR-6 study.. Journal of Clinical Oncology, 2017, 35, e12552-e12552.	0.8	1
38	Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer. Anticancer Research, 2005, 25, 1309-14.	0.5	1